Boston Consulting Group announced it has entered a strategic collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA). The collaboration will leverage artificial intelligence and generative artificial intelligence (AI and GenAI) to potentially enable the discovery and assessment of novel drug targets.